NaCl-Dextra Fertility Clinic-iron deficiency-infertility

NaCl-Dextra Fertility Clinic-iron deficiency-infertility refers to the clinical trial protocol (NCT04510870) conducted by the Dextra Fertility Clinic in Helsinki, Finland. The study is a randomized, double-blind, crossover trial designed to evaluate the impact of intravenous iron supplementation on reproductive outcomes in infertile women with iron deficiency (defined as serum ferritin levels ≤30 μg/L). The active intervention in the trial is ferric carboxymaltose (marketed as Ferinject), which is compared against a placebo of sodium chloride (NaCl) infusion. The primary objective is to determine if correcting iron deficiency improves embryo quality, specifically the number of good quality blastocysts, and subsequent pregnancy rates in women undergoing IVF or ICSI treatments. Ferric carboxymaltose is an iron-carbohydrate complex that allows for the controlled release of iron into the reticuloendothelial system, where it binds to transferrin and ferritin to replenish iron stores and support iron-dependent physiological processes essential for oocyte quality and endometrial receptivity.

Brand names

Ferinject

Other names

IDI: Ferric Carboxymaltose for InfertilityIron Deficiency as an Ignored Cause of Infertility